ArticleScience translational medicine2021
Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 60 citations in OpenAlex.
- Animal models of chronic graft-versus-host disease with oral involvement: A review.European journal of oral sciences · 2026Review
- GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.JCI insight · 2026Article
- Aberrant activation of tissue-resident lymphocytes and pro-fibrotic GZMK⁺ CD8⁺ T cells in IPF.Communications biology · 2026Article
- Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.Journal of translational medicine · 2026Review
- Novel pathogenicFrontiers in immunology · 2026Article
- Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.Frontiers in immunology · 2026Review
- CD74Journal of translational medicine · 2025Article
- Review
- Article
- Adapting systems biology to address the complexity of human disease in the single-cell era.Nature reviews. Genetics · 2025Review
- Cellular therapies for the prevention and treatment of acute graft-versus-host disease.Stem cells (Dayton, Ohio) · 2025Review
- Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome.JCI insight · 2025Article
- In vivo antibody labeling route and fluorophore dictate labeling efficiency, sensitivity, and longevity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.medRxiv : the preprint server for health sciences · 2025Article
- Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-versus-host disease due to imbalanced gut microbiota and bile acid metabolism.Journal of translational medicine · 2024Article
- CD74 supports accumulation and function of regulatory T cells in tumors.Nature communications · 2024Article
- Tissue-resident memory T cells: decoding intra-organ diversity with a gut perspective.Inflammation and regeneration · 2024Review
- Autophagy differentially regulates tissue tolerance of distinct target organs in graft-versus-host disease models.The Journal of clinical investigation · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 1 country.
Victor TkachevDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. victor.tkachev@childrens.harvard.edu leslie.kean@childrens.harvard.edu.ORCID 0000-0001-6011-0576
James KaminskiDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5137-7516
E Lake PotterVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20858, USA.ORCID 0000-0003-4339-9800
Scott N FurlanFred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington, Seattle, WA 98109, USA.
Alison YuDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Daniel J HuntDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Connor McGuckinDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8860-9926
Hengqi ZhengUniversity of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-0575-6475
Lucrezia ColonnaFred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington, Seattle, WA 98109, USA.
Ulrike GerdemannDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-3600-0366
Judith CarlsonUniversity of Washington, Seattle, WA 98195, USA.
Michelle HoffmanFred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0003-1078-6740
Joe OlveraDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-2254-5223
Chris EnglishWashington National Primate Research Center, Seattle, WA 98195, USA.ORCID 0000-0002-7229-3258
Audrey BaldessariWashington National Primate Research Center, Seattle, WA 98195, USA.ORCID 0000-0001-6392-3230
Angela Panoskaltsis-MortariDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55454, USA.ORCID 0000-0003-1802-1785
Benjamin WatkinsEmory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-6675-8071
Muna QayedEmory University School of Medicine, Atlanta, GA 30322, USA.
Yvonne SuessmuthEmory University School of Medicine, Atlanta, GA 30322, USA.
Kayla BetzDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Brandi BratrudeDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1498-1001
Amelia LangstonEmory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-0649-1915
John T HoranEmory University School of Medicine, Atlanta, GA 30322, USA.
Jose Ordovas-MontanesBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-5444-5601
Alex K ShalekBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-5670-8778
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55454, USA.ORCID 0000-0002-9608-9841
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20858, USA.ORCID 0000-0001-7448-7040
Leslie S KeanDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. victor.tkachev@childrens.harvard.edu leslie.kean@childrens.harvard.edu.ORCID 0000-0003-0475-3926
Dana-Farber Cancer Institute · USEmory University · USBroad Institute · USFred Hutch Cancer Center · USNational Institute of Allergy and Infectious Diseases · USUniversity of Minnesota Medical Center · USUniversity of Washington · US
Funding
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8MTransplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ADAMS, ANDREW B · 2002 to 2022
$54.1MTrial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI John E. Wagner · 1995 to 2026
$48.2MSTRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4MNovel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MDevelopment of NHP Models for Infectious Pathogens of ManZIAAI005161 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2020 to 2025
$6.3MIN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MIn Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4MCharacterizing the molecular signature of chronic graft-versus-host disease following hematopoietic stem cell transplantationK23HL136900 · NHLBI · EMORY UNIVERSITY · PI WATKINS, BENJAMIN · 2017 to 2021
$619kFDA HHS R01 FD004099NCI NIH HHS P01 CA065493NHLBI NIH HHS K23 HL136900NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL095791NIAID NIH HHS R01 AI034495NIAID NIH HHS R37 AI034495NIAID NIH HHS U19 AI051731NIDDK NIH HHS P30 DK034854NIH HHS P51 OD010425
Abstract
Organ infiltration by donor T cells is critical to the development of acute graft-versus-host disease (aGVHD) in recipients after allogeneic hematopoietic stem cell transplant (allo-HCT). However, deconvoluting the transcriptional programs of newly recruited donor T cells from those of tissue-resident T cells in aGVHD target organs remains a challenge. Here, we combined the serial intravascular staining technique with single-cell RNA sequencing to dissect the tightly connected processes by which donor T cells initially infiltrate tissues and then establish a pathogenic tissue residency program in a rhesus macaque allo-HCT model that develops aGVHD. Our results enabled creation of a spatiotemporal map of the transcriptional programs controlling donor CD8
Indexed as
Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAcute DiseaseAnimalsCD8-Positive T-LymphocytesHumansMacaca mulattaTissue Donors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.